Navigation Links
RTOG activates study to determine best treatment strategies for patients with glioma brain tumors
Date:12/15/2011

Treatment remains controversial for patients diagnosed with a low-risk, low-grade glioma (LGG) brain tumor. These patients have significantly better prognosis than patients diagnosed with more aggressive high-grade glioma, and their clinical care often involves ongoing observation for tumor changes with imaging studies. Because low-risk LGG are slow growing tumors, concerns about the potential adverse effects of early treatment on patients' neurocognitive function (NCF) and quality of life (QOL) may outweigh treatment benefits in patients who are frequently young and highly functional.

Although a low-grade tumor, LGG has a significant potential for transforming into a high-grade glioma. "Currently there is no consensus on when and how best to treat this tumor," says RTOG 0925 principal investigator Ali K. Choucair, M.D., Director of Neuro-oncology and Co-director of the Brain Tumor Center at the Neuroscience Institute, Norton Healthcare System, Louisville, KY. "The RTOG 0925 study was designed with compilation of best available data from both prospective as well as retrospective studies in an effort to identify early clinical and neurocognitive changes that could precede changes observed on imaging scans and could trigger early and timely treatment," Choucair explains.

The study's goal is to better understand the affects of tumor progression on patients with low-risk LGG. The phase II trial will enroll 170 study participants with newly diagnosed LGG who are undergoing observation alone for clinical care. The study will compare NCF, QOL, and seizure control over time in patients who have evidence of tumor progression versus patients who have no evidence of progression as determined by magnetic imaging resonance (MRI) scans. "Standardized and clinically meaningful definitions of tumor progression in low-risk LGG are clearly needed to further the examination and understanding of these tumors," says Walter J. Curran, Jr., MD, RTOG Group Chair, and Executive Director of the Winship Cancer Institute of Emory University in Atlanta, "It is hoped the study's findings will help guide future treatment decisions for these patients," Curran concludes.

The study also has an important translational research component that is expected to contribute much needed information to current limited knowledge about the role molecular markers in predicting LGG tumor progression. Tumor tissue from consenting study participants will be used to evaluate molecular correlates of NCF, QOL, seizure control, and progression-free survival. Such information has the potential to aid clinical decision-making and further the identification of individualized patient therapy approaches.

Patients who have disease progression while enrolled on RTOG 0925 may be eligible for entry on a trial available to RTOG members through the NCI Clinical Trials Support Unit (CTSU) sponsored by ECOG, E3F05/RTOG 1072, Phase III Randomized Study of Radiotherapy With Versus Without Temozolomide in Patients With Symptomatic or Progressive Low-Grade Gliomas.


'/>"/>
Contact: Nancy Fredericks
nfredericks@acr.org
215-717-2769
American College of Radiology
Source:Eurekalert

Related medicine news :

1. Molecule Nutlin-3a activates a signal inducing cell death and senescence in primary brain tumors
2. Targeted therapy reactivates guardian of the genome in resistant cancer
3. Transcendental Meditation activates default mode network, the brains natural ground state
4. Arsenic exposure activates an oncogenic signaling pathway; leads to increased cancer risk
5. Heart failure study: Health-literate patients not always adept at managing care
6. Higher Hospital Admissions Equal Higher Readmissions: Study
7. Study takes aim at education-based death rate disparities
8. Study Finds Fewer Blood Transfusions Needed After Hip Surgeries
9. Wayne State study shows early research on cellphone conversations likely overestimated crash risk
10. Heart drug may be effective for managing certain cancers: Queens University study
11. Working Moms Happier, Healthier Than Stay-at-Home Peers: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Research and ... Market for Companion Diagnostic Tests" report to their offering. ... for Companion Diagnostics The World Market for ... personalized medicine diagnostics. Market analysis in the report includes the ... Market (In Vitro Diagnostic Kits) by Region (N. America, EU, ...
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
Breaking Medicine Technology: